In response to the Coldrif cough syrup tragedy that resulted in the deaths of 24 children in Madhya Pradesh, the Central Drugs Standard Control Organisation (CDSCO) is set to meet with the pharmaceutical industry to discuss the safety of high-risk solvents used in pediatric formulations. The Drugs Controller General of India, Dr. Rajeev Singh Raghuvanshi, raised concerns regarding solvents like propylene glycol and its impurities, which have been linked to contamination risks in oral liquid formulations. The memorandum issued on May 11, 2026, highlights the urgent need for consultations with stakeholders to assess current manufacturing practices and consider alternative excipients. The tragic incident involved Coldrif syrup, produced by Sresan Pharmaceuticals, which contained 48.6% diethylene glycol, far exceeding the permissible limit. Following this, the WHO issued a global alert, and significant regulatory actions were taken, including the permanent revocation of Sresan Pharma's license and the arrest of its owner for culpable homicide. The upcoming meeting aims to ensure the safety of pediatric medications and prevent future tragedies.